Navellier & Associates’s Biogen BIIB Stock Holding History

Navellier & Associates’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$468K	Hold	2,164	–	–	0.04%	255
2026 Q1	$397K	Hold	2,164	–	–	0.04%	245
2025 Q4	$381K	Hold	2,164	–	–	0.04%	253
2025 Q3	$303K	Hold	2,164	–	–	0.03%	315
2025 Q2	$272K	Hold	2,164	–	–	0.03%	272
2025 Q1	$264K	Hold	2,164	–	–	0.04%	270
2024 Q4	$331K	Hold	2,164	–	–	0.04%	269
2024 Q3	$419K	Hold	2,164	–	–	0.06%	242
2024 Q2	$502K	Hold	2,164	–	–	0.06%	242
2024 Q1	$467K	Hold	2,164	–	–	0.06%	251
2023 Q4	$560K	Hold	2,164	–	–	0.08%	207
2023 Q3	$556K	Buy	+2,164	New	+$579K	0.1%	195
2016 Q1	–	Sell	-3,146	Closed	-$964K	–	263
2015 Q4	$964K	Sell	3,146 -1,600	-34%	-$460K	0.11%	88
2015 Q3	$1.39M	Sell	4,746 -71,087	-94%	-$23.5M	0.14%	70
2015 Q2	$30.6M	Buy	75,833 +1,953	+3%	+$784K	2.69%	10
2015 Q1	$31.2M	Sell	73,880 -92,993	-56%	-$36.7M	2.83%	12
2014 Q4	$56.6M	Sell	166,873 -8,596	-5%	-$2.78M	2.83%	10
2014 Q3	$58M	Sell	175,469 -22,304	-11%	-$7.35M	2.92%	10
2014 Q2	$62.4M	Sell	197,773 -15,545	-7%	-$4.68M	2.82%	8
2014 Q1	$65.2M	Sell	213,318 -3,282	-2%	-$1.04M	3.04%	8
2013 Q4	$60.6M	Sell	216,600 -108,796	-33%	-$28.1M	2.73%	9
2013 Q3	$78.3M	Sell	325,396 -9,044	-3%	-$2.02M	2.31%	2
2013 Q2	$72M	Buy	+334,440	New	+$71.5M	3.43%	3

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Navellier & Associates's BIIB Position: Q2 2026 in Review

Navellier & Associates held its Biogen (BIIB) position steady in Q2 2026 at 2,164 shares worth $468K. The position accounts for 0.04% of the portfolio, ranked #255.

Navellier & Associates first reported a position in BIIB in Q2 2013 and has held it in 23 quarters since. The position peaked at $78.3M in Q3 2013. 1,045 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Navellier & Associates held 2,164 shares of Biogen worth $468K as of Q2 2026.
Navellier & Associates left its Biogen share count unchanged in Q2 2026.
Biogen made up 0.04% of Navellier & Associates's portfolio in Q2 2026, its #255 holding.
Navellier & Associates first reported a position in Biogen in Q2 2013 and has held it in 23 quarters since.
Navellier & Associates's Biogen position peaked at $78.3M in Q3 2013.
1,045 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Navellier & Associates's 13F filing for Q2 2026, filed 4 Aug 2026.